Literature DB >> 15285589

[New Modern Magpi: meatal advancement and glanuloplasty clinical course].

I Somoza1, J Liras, A S Abuín, R Méndez, M G Tellado, J Ríos, E Pais, D Vela.   

Abstract

INTRODUCTION: Meatal advancement and glanuloplasty (MAGPI) described by Duckett, has been the most accepted technique for distal hypospadias repair along the last 20 years. Only 50% of the distal variants are amenable to the Magpi; last years several modifications has been reported in order to reach better cosmetic results and to make it available for the most of the distal hypospadias. We report the first 20 cases with some modifications of Magpi.
MATERIALS AND METHODS: The basic steps of the technique are: we remove a triangular segment of glanular tissue distal to the meatus. Dissection of the dorsal and lateral urethral sides is made, accomplishing the urethral advancement without any tension. Strips of glandular epithelium are excised on each side, and glans tissue is sutured above the ventral urethral wall.
RESULTS: There were 11 coronal, and 9 glanular hypospadias (3 with megameatus). 8 cases showed a slight incurvation that disappeared after releasing any cutaneous chordee. The posoperative follow-up was 35 weeks (R=7-48 weeks). Cosmetic and functional results were excellent, showing a natural circumcized penis. There wasn't any complications as meatal retraction, stenosis or incurvation. There was only a transitional hematoma and a minimal fistula that closed expontanely.
CONCLUSIONS: New Modern Magpi adds minimal variations to the original technique, avoiding the cosmetic limitations derived from borderline indications. New Modern Magpi is amenable to near all of glanular hypospadias and most of coronal hypospadias.

Entities:  

Mesh:

Year:  2004        PMID: 15285589

Source DB:  PubMed          Journal:  Cir Pediatr        ISSN: 0214-1221


  1 in total

1.  MAGPI hypospadias repair: factors that determine outcome.

Authors:  M A Abdelrahman; K M O'Connor; E A Kiely
Journal:  Ir J Med Sci       Date:  2013-03-03       Impact factor: 1.568

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.